We propose that NOX2-derived ROS may contribute to the progression of KRAS-induced leukemia and that strategies to target NOX2 merit further evaluation in RAS-mutated hematopoietic cancer. This evidence concerns the gene KRAS and hematopoietic and lymphoid cell neoplasm.